Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1998 Jul;53(7):583–585. doi: 10.1136/thx.53.7.583

Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease

M Confalonieri 1, E Mainardi 1, P Della 1, S Bernorio 1, L Gandola 1, B Beghe 1, A Spanevello 1
PMCID: PMC1745263  PMID: 9797758

Abstract

BACKGROUND—Airways inflammation is a feature of chronic obstructive pulmonary disease (COPD), but the role of corticosteroids in the management of clinically stable patients has yet to be established. A randomised controlled study was carried out to investigate the effect of high dose inhaled beclomethasone dipropionate (BDP) administered for two months to patients with stable, smoking related COPD. Sputum induction was used to evaluate bronchial inflammation response.
METHODS—34 patients (20 men and 14 women) were examined on three separate occasions. At the initial clinical assessment (visit 0), spirometry and blood gas analysis were performed. On visit 1 (within one week of visit 0) sputum induction was performed and each patient was randomised to receive either BDP 500 µg three times daily (treated group) or nothing (control group). After two months (visit 2), all patients underwent repeat clinical assessment, spirometry, and sputum induction.
RESULTS—There were no differences in sputum cell counts between the groups at baseline. After two months of treatment, induced sputum samples from patients in the treated group showed a reduction in both neutrophils (−27%) and total cells (−42%) with respect to baseline, while the control group did not (neutrophils +9%, total cells +7%). Macrophages increased in the treated group but not in the control group. The mean final value of sputum neutrophils was 52% in the treated group and 73.3% in the control group (95% confidence interval (CI) −27.2 to −15.4). The mean final value of sputum macrophages was 35.8% in treated group and 19.3% in control group (95% CI 10.3 to 22.8). The differences between the treated and control groups for neutrophils (−21.3%), macrophages (+16.5%), and total cells (−65%) were significant. Spirometry and blood gas data did not change from baseline in either patient group.
CONCLUSIONS—A two month course of treatment with high dose inhaled BDP reduces significantly neutrophil cell counts in patients with clinically stable, smoking related COPD. Further studies on the effectiveness of inhaled steroids in COPD are needed to confirm the clinical importance of this observation.



Full Text

The Full Text of this article is available as a PDF (105.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chanez P., Vignola A. M., O'Shaugnessy T., Enander I., Li D., Jeffery P. K., Bousquet J. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med. 1997 May;155(5):1529–1534. doi: 10.1164/ajrccm.155.5.9154853. [DOI] [PubMed] [Google Scholar]
  2. Keatings V. M., Jatakanon A., Worsdell Y. M., Barnes P. J. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med. 1997 Feb;155(2):542–548. doi: 10.1164/ajrccm.155.2.9032192. [DOI] [PubMed] [Google Scholar]
  3. Llewellyn-Jones C. G., Harris T. A., Stockley R. A. Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Am J Respir Crit Care Med. 1996 Feb;153(2):616–621. doi: 10.1164/ajrccm.153.2.8564107. [DOI] [PubMed] [Google Scholar]
  4. Pavord I. D., Pizzichini M. M., Pizzichini E., Hargreave F. E. The use of induced sputum to investigate airway inflammation. Thorax. 1997 Jun;52(6):498–501. doi: 10.1136/thx.52.6.498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Renkema T. E., Schouten J. P., Koëter G. H., Postma D. S. Effects of long-term treatment with corticosteroids in COPD. Chest. 1996 May;109(5):1156–1162. doi: 10.1378/chest.109.5.1156. [DOI] [PubMed] [Google Scholar]
  6. Siafakas N. M., Vermeire P., Pride N. B., Paoletti P., Gibson J., Howard P., Yernault J. C., Decramer M., Higenbottam T., Postma D. S. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J. 1995 Aug;8(8):1398–1420. doi: 10.1183/09031936.95.08081398. [DOI] [PubMed] [Google Scholar]
  7. Spanevello A., Migliori G. B., Sharara A., Ballardini L., Bridge P., Pisati P., Neri M., Ind P. W. Induced sputum to assess airway inflammation: a study of reproducibility. Clin Exp Allergy. 1997 Oct;27(10):1138–1144. [PubMed] [Google Scholar]
  8. Stănescu D., Sanna A., Veriter C., Kostianev S., Calcagni P. G., Fabbri L. M., Maestrelli P. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax. 1996 Mar;51(3):267–271. doi: 10.1136/thx.51.3.267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. de Guia T. S. Inhaled corticosteroids in COPD. A light at the end of the tunnel? Chest. 1995 Dec;108(6):1486–1487. doi: 10.1378/chest.108.6.1486. [DOI] [PubMed] [Google Scholar]
  10. van Schayck C. P., van Grunsven P. M., Dekhuijzen P. N. Do patients with COPD benefit from treatment with inhaled corticosteroids? Eur Respir J. 1996 Oct;9(10):1969–1972. doi: 10.1183/09031936.96.09101969. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES